Limits...
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH

Related in: MedlinePlus

Bevacizumab-based therapies and progression-free survival (PFS) in patients with metastatic colorectal cancer. (a) Kaplan–Meier estimates for PFS. Subgroups according to the baseline serum carcinoembryonic antigen (CEA) levels, categorized at the observed median of 26.8 ng/mL. (b) Hazard of progression versus baseline CEA serum level, relative to the median baseline serum CEA level (26.8 ng/mL) with point-wise 95% confidence intervals.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317865&req=5

fig02: Bevacizumab-based therapies and progression-free survival (PFS) in patients with metastatic colorectal cancer. (a) Kaplan–Meier estimates for PFS. Subgroups according to the baseline serum carcinoembryonic antigen (CEA) levels, categorized at the observed median of 26.8 ng/mL. (b) Hazard of progression versus baseline CEA serum level, relative to the median baseline serum CEA level (26.8 ng/mL) with point-wise 95% confidence intervals.

Mentions: As shown in Figure 2 and Table 2, the median PFS for patients receiving bevacizumab-based treatment was 8.5 months in group I and 6.4 months in group II (P = 0.023). One-year PFS rates were 24% (95% CI 15–36%) in group I, and 13% (95% CI 7–25%) in group II (Table 2, Fig. 2a). The hazard ratio (HR) of group II versus group I was 1.47 (95% CI, 1.05–2.05). This HR was virtually unchanged if adjusted for T and N (HR, 1.47; 95% CI, 1.04–2.09). Figure 2(b) depicts the hazard of progression at various baseline serum CEA levels, relative to the median level of 26.8 ng/mL. This analysis indicates the almost linear dependency of the progression risk on the baseline serum CEA level. Compared to the median level of 26.8 ng/mL, patients with CEA levels of >69 ng/mL were at a significantly elevated risk for progression. In contrast, the progression risk appeared to be lower for patients with CEA levels lower than 26.8 ng/mL, but a significance level was not reached.


Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Bevacizumab-based therapies and progression-free survival (PFS) in patients with metastatic colorectal cancer. (a) Kaplan–Meier estimates for PFS. Subgroups according to the baseline serum carcinoembryonic antigen (CEA) levels, categorized at the observed median of 26.8 ng/mL. (b) Hazard of progression versus baseline CEA serum level, relative to the median baseline serum CEA level (26.8 ng/mL) with point-wise 95% confidence intervals.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317865&req=5

fig02: Bevacizumab-based therapies and progression-free survival (PFS) in patients with metastatic colorectal cancer. (a) Kaplan–Meier estimates for PFS. Subgroups according to the baseline serum carcinoembryonic antigen (CEA) levels, categorized at the observed median of 26.8 ng/mL. (b) Hazard of progression versus baseline CEA serum level, relative to the median baseline serum CEA level (26.8 ng/mL) with point-wise 95% confidence intervals.
Mentions: As shown in Figure 2 and Table 2, the median PFS for patients receiving bevacizumab-based treatment was 8.5 months in group I and 6.4 months in group II (P = 0.023). One-year PFS rates were 24% (95% CI 15–36%) in group I, and 13% (95% CI 7–25%) in group II (Table 2, Fig. 2a). The hazard ratio (HR) of group II versus group I was 1.47 (95% CI, 1.05–2.05). This HR was virtually unchanged if adjusted for T and N (HR, 1.47; 95% CI, 1.04–2.09). Figure 2(b) depicts the hazard of progression at various baseline serum CEA levels, relative to the median level of 26.8 ng/mL. This analysis indicates the almost linear dependency of the progression risk on the baseline serum CEA level. Compared to the median level of 26.8 ng/mL, patients with CEA levels of >69 ng/mL were at a significantly elevated risk for progression. In contrast, the progression risk appeared to be lower for patients with CEA levels lower than 26.8 ng/mL, but a significance level was not reached.

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH
Related in: MedlinePlus